Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Cash & Current Investments (2016 - 2025)

STRATA Skin Sciences' Cash & Current Investments history spans 15 years, with the latest figure at $7.9 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 7.95% to $7.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.9 million, a 7.95% decrease, with the full-year FY2025 number at $7.9 million, down 7.95% from a year prior.
  • Cash & Current Investments hit $7.9 million in Q4 2025 for STRATA Skin Sciences, up from $7.1 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for SSKN hit a ceiling of $17.5 million in Q1 2021 and a floor of $4.2 million in Q1 2023.
  • Historically, Cash & Current Investments has averaged $9.4 million across 5 years, with a median of $8.4 million in 2023.
  • Biggest five-year swings in Cash & Current Investments: tumbled 61.68% in 2023 and later soared 56.98% in 2024.
  • Tracing SSKN's Cash & Current Investments over 5 years: stood at $12.6 million in 2021, then tumbled by 46.01% to $6.8 million in 2022, then grew by 19.47% to $8.1 million in 2023, then rose by 5.88% to $8.6 million in 2024, then decreased by 7.95% to $7.9 million in 2025.
  • Business Quant data shows Cash & Current Investments for SSKN at $7.9 million in Q4 2025, $7.1 million in Q3 2025, and $6.0 million in Q2 2025.